Skip to main content
Premium Trial:

Request an Annual Quote

US District Court Dismisses Patent-Infringement Suit Against ABI, PerkinElmer

NEW YORK, April 3 - Applied Biosystems today said that the US District Court for the District of Connecticut has dismissed "all claims" brought by On-Line Technologies against ABI, PerkinElmer, and Sick.

According to ABI, On-Line filed the suit in early November 1999 claiming that these companies infringed a patent and misappropriated a trade secret, "among other things," related to products manufactured by former divisions of ABI that were sold to PerkinElmer and Sick.

 

On-Line Technologies, which has since been acquired by MKS Instruments, filed claims for "patent infringement, trade secret misappropriation, fraud, breach of contract, and unfair trade practices against Applera, PerkinElmer, and Sick," ABI spokeswoman Lori Murray said in an e-mail to GenomeWeb.

The complaint argued that products called Spectrum One and MCS100E, which were made by former ABI division that later were sold to PerkinElmer and Sick, "were based on allegedly proprietary information belonging to On-Line Technologies and that the MCS100E infringed U.S. Patent No. 5,440,143. The case was actually dismissed March 31.

 

Officials from MKS Instruments did not return a telephone call seeking comment. A PerkinElmer spokesman declined to comment.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.